Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (301-310 of 373) with videos related to

Pageof 38
Sort By:
Journal of the American Academy of Dermatology|July 5, 2020
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapyZachary E Holcomb, Monica Rosales Santillan, Peyton C Morss-Walton, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Dermatology and Therapy|January 6, 2024
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported OutcomesAlexa B Kimball, Joslyn Kirby, John R Ingram, et al.
American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 7, 2018
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety DatabaseMegan E B Clowse, Angela E Scheuerle, Christina Chambers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 4, 2025
Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burdenJ R Ingram, A V Marzano, E Prens, et al.
The British Journal of Dermatology|July 22, 2014
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentA B Kimball, G B E Jemec, M Yang, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 17, 2017
Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)N H Shear, R Alhusayen, A Fernandez-Obregon, et al.
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Pageof 38

Showing results (301-310 of 373) with videos related to

Sort By:
Pageof 38
Journal of the American Academy of Dermatology|July 5, 2020
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapyZachary E Holcomb, Monica Rosales Santillan, Peyton C Morss-Walton, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Dermatology and Therapy|January 6, 2024
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported OutcomesAlexa B Kimball, Joslyn Kirby, John R Ingram, et al.
American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 7, 2018
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety DatabaseMegan E B Clowse, Angela E Scheuerle, Christina Chambers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 4, 2025
Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burdenJ R Ingram, A V Marzano, E Prens, et al.
The British Journal of Dermatology|July 22, 2014
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentA B Kimball, G B E Jemec, M Yang, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 17, 2017
Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)N H Shear, R Alhusayen, A Fernandez-Obregon, et al.
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Pageof 38